<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cad Saude Publica</journal-id><journal-id journal-id-type="iso-abbrev">Cad Saude Publica</journal-id><journal-id journal-id-type="publisher-id">csp</journal-id><journal-title-group><journal-title>Cadernos de Sa&#x000fa;de P&#x000fa;blica</journal-title></journal-title-group><issn pub-type="ppub">0102-311X</issn><issn pub-type="epub">1678-4464</issn><publisher><publisher-name>Escola Nacional de Sa&#x000fa;de P&#x000fa;blica Sergio Arouca, Funda&#x000e7;&#x000e3;o Oswaldo Cruz</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40008709</article-id><article-id pub-id-type="pmc">PMC11863634</article-id><article-id pub-id-type="doi">10.1590/0102-311XEN178623</article-id><article-id pub-id-type="other">01410</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>TB antigen-based skin tests and QFT-Plus for <italic>Mycobacterium
tuberculosis</italic> infection diagnosis in Brazilian healthcare workers: a
cost-effectiveness analysis</article-title><trans-title-group xml:lang="pt"><trans-title>Testes cut&#x000e2;neos baseados em ant&#x000ed;genos de tuberculose e QFT-Plus
para diagn&#x000f3;stico da infec&#x000e7;&#x000e3;o por Mycobacterium tuberculosis em profissionais
de sa&#x000fa;de brasileiros: uma an&#x000e1;lise de custo-efetividade</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title>Pruebas cut&#x000e1;neas basadas en ant&#x000ed;genos de tuberculosis y QFT-Plus
para el diagn&#x000f3;stico de infecci&#x000f3;n por Mycobacterium tuberculosis en
profesionales de la salud brasile&#x000f1;os: un an&#x000e1;lisis de
costo-efectividad</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2093-8816</contrib-id><name><surname>de Souza</surname><given-names>Fernanda Mattos</given-names></name><role>contributed with the study conception, data analysis</role><role>writing, and review</role><role>approved the final version</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9733-5098</contrib-id><name><surname>Steffen</surname><given-names>Ricardo E.</given-names></name><role>contributed with the study conception, data analysis</role><role>interpretation, and review</role><role>approved the final version</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7568-5014</contrib-id><name><surname>Pinto</surname><given-names>M&#x000e1;rcia Ferreira Teixeira</given-names></name><role>contributed with the study conception, data analysis</role><role>interpretation, and review</role><role>approved the final version</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8132-6288</contrib-id><name><surname>do Prado</surname><given-names>Thiago Nascimento</given-names></name><role>contributed with the data interpretation and review</role><role>approved the final version</role><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4826-3355</contrib-id><name><surname>Maciel</surname><given-names>Ethel Leonor Noia</given-names></name><role>contributed with the data interpretation and review</role><role>approved the final version</role><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4000-4984</contrib-id><name><surname>Trajman</surname><given-names>Anete</given-names></name><role>contributed with the study conception, data interpretation</role><role>writing, and review</role><role>approved the final version</role><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label> Universidade do Estado do Rio de Janeiro, Rio de Janeiro,
Brasil.</aff><aff id="aff2">
<label>2</label> Centro Biom&#x000e9;dico, Universidade do Estado do Rio de Janeiro, Rio de
Janeiro, Brasil.</aff><aff id="aff3">
<label>3</label> Instituto Nacional de Sa&#x000fa;de da Mulher, da Crian&#x000e7;a e do Adolescente
Fernandes Figueira, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Rio de Janeiro, Brasil.</aff><aff id="aff4">
<label>4</label> Programa de P&#x000f3;s-gradua&#x000e7;&#x000e3;o em Sa&#x000fa;de Coletiva, Universidade Federal
do Esp&#x000ed;rito Santo, Vit&#x000f3;ria, Brasil.</aff><aff id="aff5">
<label>5</label> Centro Biom&#x000e9;dico, Universidade Federal do Esp&#x000ed;rito Santo, Vit&#x000f3;ria,
Brasil.</aff><aff id="aff6">
<label>6</label> McGill University, Montreal, Canada.</aff><aff id="aff7">
<label>7</label> Universidade Federal do Rio de Janeiro, Rio de Janeiro,
Brasil.</aff><author-notes><corresp id="c1">
<label>Correspondence</label> A. Trajman Rua Macedo Sobrinho 74, apto. 203, Rio
de Janeiro, RJ 22271-080, Brasil. <email>atrajman@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>24</day><month>2</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>41</volume><issue>1</issue><elocation-id>e00178623</elocation-id><history><date date-type="received"><day>22</day><month>9</month><year>2023</year></date><date date-type="rev-recd"><day>08</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2024</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License</license-p></license></permissions><abstract><p>This study aimed to analyze the cost-effectiveness of three tuberculosis (TB)
antigen-based skin tests (TBST) (Diaskintest, C-TST, and Cy-TB) and QFT-Plus for
TB infection diagnosis compared to the current standard of care, PPD Rt-23
tuberculin skin test (TST), among healthcare workers in Brazil. A
state-transition Markov model was employed, simulating a cohort of healthcare
workers (five annual cycles) for testing and treating TB infection with three
months of weekly doses of rifapentine and isoniazid (3HP) under the Brazilian
public health system perspective. Effects (TB disease averted) and costs for
screening and treating TB infection were discounted at 5%. Incremental
cost-effectiveness per TB averted was estimated. One-way and probabilistic
sensitivity analysis were performed. Brazil, an upper-middle-income country with
a high burden of TB, shows one of the largest universal public health systems
and provides free-of-charge diagnosis and treatment for TB and TB infection. TST
is the standard of care, whereas QFT-Plus is available for very high-risk
populations. The three new TBST are under validation for eventual incorporation.
Patients or participants: a hypothetical cohort of 10,000 healthcare workers,
working at any level of healthcare service, and negative TST results in the
previous year of both sexes with a baseline negative TST result. Diaskintest,
C-TST, Cy-TB, and QFT-Plus were found to show a higher specificity. Costs with
QFT-Plus were higher due to equipment, human labor, and test price. Diaskintest
was the most cost-saving strategy, followed by Cy-TB for TB preventive treatment
with 3HP. In the Brazilian scenario, Diaskintest and Cy-TB are the most
cost-effective tests for sequential testing of healthcare workers.</p></abstract><trans-abstract xml:lang="pt"><p>Este estudo objetivou analisar o custo-efetividade de tr&#x000ea;s testes cut&#x000e2;neos
baseados em ant&#x000ed;genos de tuberculose (TB) (Diaskintest, C-TST, Cy-TB) e QFT-Plus
para diagn&#x000f3;stico de infec&#x000e7;&#x000e3;o por TB comparando-os ao padr&#x000e3;o de atendimento
atual, PPD Rt-23 teste tubercul&#x000ed;nico (TT), entre profissionais de sa&#x000fa;de no
Brasil. Trata-se de um modelo de Markov de transi&#x000e7;&#x000e3;o de estado, simulando uma
coorte de profissionais de sa&#x000fa;de (cinco ciclos anuais) para testagem e
tratamento de infec&#x000e7;&#x000e3;o por TB com doses semanais de rifapentina e isoniazida por
tr&#x000ea;s meses (3HP) sob a perspectiva do sistema p&#x000fa;blico de sa&#x000fa;de brasileiro. Os
efeitos (TB evitada) e os custos de triagem e tratamento da infec&#x000e7;&#x000e3;o foram
descontados em 5%. O custo-efetividade incremental por TB evitada foi calculado.
Foram realizadas an&#x000e1;lises de sensibilidade unidirecionais e probabil&#x000ed;sticas. O
Brasil, um pa&#x000ed;s de renda m&#x000e9;dia-alta com alta carga de TB, possui um dos maiores
sistemas p&#x000fa;blicos universais de sa&#x000fa;de e oferece diagn&#x000f3;stico e tratamento
gratuitos para TB. O TT &#x000e9; o atendimento padr&#x000e3;o, o QFT-Plus est&#x000e1; dispon&#x000ed;vel para
popula&#x000e7;&#x000f5;es de risco muito elevado. Os tr&#x000ea;s novos testes cut&#x000e2;neos est&#x000e3;o em
valida&#x000e7;&#x000e3;o para eventual incorpora&#x000e7;&#x000e3;o. Uma coorte hipot&#x000e9;tica de 10 mil
profissionais de sa&#x000fa;de, trabalhando em qualquer n&#x000ed;vel de atendimento, e
resultados negativos de TT no ano anterior de ambos os sexos com um resultado de
TT negativo na linha de base. Diaskintest, C-TST, Cy-TB e QFT-Plus t&#x000ea;m maior
especificidade. Os custos com o QFT-Plus foram maiores devido: equipamento, m&#x000e3;o
de obra e custo da testagem. O Diaskintest foi a estrat&#x000e9;gia de maior economia,
seguido pelo Cy-TB para tratamento preventivo da TB com 3HP. No cen&#x000e1;rio
brasileiro, Diaskintest e Cy-TB s&#x000e3;o os testes mais custo-efetivos para testagem
sequencial de profissionais da sa&#x000fa;de.</p></trans-abstract><trans-abstract xml:lang="es"><p>Este estudio tuvo como objetivo analizar el costo-efectividad de tres pruebas
cut&#x000e1;neas basadas en ant&#x000ed;genos de tuberculosis (TB) (Diaskintest, C-TST, Cy-TB) y
QFT-Plus para diagnosticar la infecci&#x000f3;n por TB compar&#x000e1;ndolas con el est&#x000e1;ndar de
atenci&#x000f3;n actual, PPD Rt-23 prueba de la tuberculina (TT), entre profesionales de
la salud en Brasil. Se trata de un modelo de Markov de transici&#x000f3;n de estado, que
simula una cohorte de profesionales de la salud (cinco ciclos anuales) para
pruebas y tratamiento de la infecci&#x000f3;n por TB con dosis semanales de rifapentina
e isoniazida durante tres meses (3HP) desde la perspectiva del sistema de salud
p&#x000fa;blica brasile&#x000f1;o. Los efectos (TB evitada) y los costos de detecci&#x000f3;n y
tratamiento de la infecci&#x000f3;n se descontaron en un 5%. Se calcul&#x000f3; el
costo-efectividad incremental por TB evitada. Se realizaron an&#x000e1;lisis de
sensibilidad unidireccionales y probabil&#x000ed;sticos. Brasil, un pa&#x000ed;s de ingresos
medianos altos con una alta carga de TB, tiene uno de los mayores sistemas de
salud p&#x000fa;blica universal y ofrece diagn&#x000f3;stico y tratamiento gratuitos para la TB.
El TT es la atenci&#x000f3;n est&#x000e1;ndar, QFT-Plus est&#x000e1; disponible para poblaciones de muy
alto riesgo. Las tres nuevas pruebas cut&#x000e1;neas se encuentran en proceso de
validaci&#x000f3;n para su eventual incorporaci&#x000f3;n. Una cohorte hipot&#x000e9;tica de 10.000
profesionales de la salud, trabajando en cualquier nivel de atenci&#x000f3;n, y
resultados de TT negativos en el a&#x000f1;o anterior de ambos sexos con resultado de TT
negativo en la l&#x000ed;nea de base. Diaskintest, C-TST, Cy-TB y QFT-Plus tienen mayor
especificidad. Los costos con QFT-Plus fueron mayores debido a: equipo, mano de
obra y costo de las pruebas. Diaskintest fue la estrategia m&#x000e1;s rentable, seguida
de Cy-TB para tratamiento preventivo de la TB con 3HP. En el escenario
brasile&#x000f1;o, Diaskintest y Cy-TB son las pruebas m&#x000e1;s rentables para realizar
pruebas secuenciales a los profesionales de la salud.</p></trans-abstract><kwd-group><title>Keywords:</title><kwd>Healthcare Workers</kwd><kwd>
<italic>Mycobacterium tuberculosis</italic> Infections</kwd><kwd>Diagnosis</kwd><kwd>Cost-Effectiveness Analysis</kwd></kwd-group><kwd-group xml:lang="pt"><title>Palavras-chave: </title><kwd>Trabalhadores da Sa&#x000fa;de</kwd><kwd>Infec&#x000e7;&#x000e3;o por <italic>Mycobacterium tuberculosis</italic>
</kwd><kwd>Diagn&#x000f3;stico</kwd><kwd>An&#x000e1;lise de Custo-Efetividade</kwd></kwd-group><kwd-group xml:lang="es"><title> Palabras-clave: </title><kwd>Trabajadores de la Salud</kwd><kwd>Infecci&#x000f3;n por <italic>Mycobacterium tuberculosis</italic>
</kwd><kwd>Diagn&#x000f3;stico</kwd><kwd>An&#x000e1;lisis de Costo-Efectividad</kwd></kwd-group><counts><fig-count count="0"/><table-count count="4"/><equation-count count="0"/><ref-count count="45"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Brazil, an upper middle-income country, holds one of the largest universal public
health systems, the Brazilian Unified National Health System (SUS, acronym in
Portuguese), which covers over 150 million people who depend exclusively on its
services. The Brazilian Ministry of Health frequently receives the highest budget of
the Federal Government. This budget is dedicated to all health activities, thus
incorporation of new technologies requires approval by an independent committee,
which evaluates evidence on safety, effectiveness, and cost-effectiveness <xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>.</p><p>Brazil is one of the 30 highest tuberculosis (TB) burden countries <xref rid="B2" ref-type="bibr">
<sup>2</sup>
</xref>. To achieve TB elimination, countries need to invest on TB preventive
treatment <xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref>. Since 2010, TB preventive treatment is recommended for all age contacts
with a positive tuberculin skin test (TST) and a normal chest X-ray in Brazil, but
uptake of TB preventive treatment has been slow <xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref>. Healthcare workers are one of the priority contact populations, thus they
should be tested for TB infection annually, and treated if conversion is detected
and the chest X-ray is normal. Frequent losses occur in their cascade-of-care,
particularly among healthcare workers with prior Bacilli Calmette-Gu&#x000e9;rin (BCG)
vaccination, who are more likely to refuse TB preventive treatment <xref rid="B5" ref-type="bibr">
<sup>5</sup>
</xref>. Pre-treatment losses, such as access to TB infection diagnostic tests, are
also an important bottleneck <xref rid="B6" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>,</sup>
<xref rid="B7" ref-type="bibr">
<sup>7</sup>
</xref>.</p><p>Following the 2018 United Nations high-level meeting recommendations <xref rid="B2" ref-type="bibr">
<sup>2</sup>
</xref>, some steps to scale up TB preventive treatment have been implemented in
Brazil, including training of healthcare workers starting in 2018; implementation of
a TB preventive treatment surveillance information system in the same year <xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref>; incorporation of the QuantiFERON-TB Gold Plus (QFT-Plus) test (Qiagen;
<ext-link xlink:href="https://www.qiagen.com/" ext-link-type="uri">https://www.qiagen.com</ext-link>) for
people living with HIV infection (PLWH), contacts aged 2-10, transplant candidates,
and people using immunosuppressive drugs in 2021 <xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref>; and incorporation of the 3HP regimen (three months of weekly doses of 900mg
rifapentine and 900mg isoniazid) as the first choice for TB preventive treatment in
2022 <xref rid="B9" ref-type="bibr">
<sup>9</sup>
</xref>.</p><p>The intermittent shortage of PPD Rt-23 (Statens Serum Institut; <ext-link xlink:href="https://en.ssi.dk/" ext-link-type="uri">https://en.ssi.dk/</ext-link>) <xref rid="B7" ref-type="bibr">
<sup>7</sup>
</xref> and the lower specificity of TST in BCG-vaccinated populations <xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref> pose significant challenges, prompting the Brazilian National Tuberculosis
Control Program (PNCT, acronym in Portuguese) to evaluate newer, more specific
tests. QFT-Plus and TB antigen-based skin tests (TBST) use the more specific
antigens, namely early secreted antigenic target 6 (ESAT-6) and culture filtrate
protein 10 (CFP-10). Currently, three tuberculosis TBST are being validated in
Brazil for eventual incorporation: Diaskintest (Generium Pharmaceutical; <ext-link xlink:href="https://www.generium.ru/en/" ext-link-type="uri">https://www.generium.ru/en/</ext-link>), C-TST (Zhifei Longcom Biologic Pharmacy
Co.; <ext-link xlink:href="https://en.zhifeishengwu.com/" ext-link-type="uri">https://en.zhifeishengwu.com</ext-link>), and Cy-TB (Serum Institute of India;
<ext-link xlink:href="https://www.seruminstitute.com/" ext-link-type="uri">https://www.seruminstitute.com/</ext-link>). QFT-Plus require laboratory
facilities and is more costly than TST <xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>. Diaskintest was found to be cheaper and more effective than TST for PLWH in
Brazil, but there is no data on cost-effectiveness of TBST in healthcare workers,
the largest eligible population for TB preventive treatment <xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>. In this study, we analyzed the cost-effectiveness of TBST and QFT-Plus
compared to TST for TB infection screening healthcare workers with a first negative
TST test from the perspective of the SUS, over a 5-year time horizon.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Setting and current policies</title><p>The SUS provides, via the PNCT and municipal health departments, free-of-charge
diagnosis and treatment for TB and TB infection. Investigation of TB infection
in healthcare workers is recommended in Brazil as part of the worker&#x02019;s
pre-employment and annual health visits, regardless of the level of healthcare
service <xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>. Healthcare workers with a first negative TST are invited to repeat the
test in one to three weeks to assess the booster effect (induration size
increment of 10mm). Individuals with a persistent negative TST then undergo a
1-step TST annually. TB preventive treatment is recommended when conversion (a
10mm increment over the latest induration size) occurs <xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>. Since March 2022, the TB preventive treatment regimen of choice is 3HP,
except for children under two years of age, contacts over 50 years of age, those
with liver disease, contacts of people with isoniazid- or
rifampicin-monoresistant TB or intolerance to isoniazid or rifapentin <xref rid="B9" ref-type="bibr">
<sup>9</sup>
</xref>. Prior to TB preventive treatment, for any indication, a chest
radiograph is mandatory to rule out TB.</p></sec><sec><title>Population, study perspective, time horizon, and discount rate</title><p>The study population consists of a hypothetical cohort of 10,000 Brazilian
healthcare workers of both sexes with an average age of 35 years, working at any
level of healthcare service and negative TST results in the previous year. The
SUS perspective was adopted for this study <xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>. Each patient with positive bacilloscopy for <italic>Mycobacterium
tuberculosis</italic> infects an average of 10 individuals per year 1 <xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>; about 1% to 5% of exposed individuals develop TB shortly after exposure
(primary TB), and 10% to 30% become infected (TB infection) <xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>. Among those with TB infection, approximately 5% to 15% will develop the
disease over their lifetime <xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref>, with a higher risk in the first 2 to 5 years after infection <xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>. A time horizon of five years was considered, as individuals are at
increased risk of developing TB in the first 2 to 5 years after TB infection
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>. This study followed the recommendation of the Brazilian Ministry of
Health, in which discount rates are standardized at 5% per year for effects and
costs to increase the comparability of studies <xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>. Additionally, it suggests using different discount rates (0% and 10%)
in sensitivity analysis to determine how much the arbitrary selection of the
rate affected the study&#x02019;s conclusion <xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>.</p></sec><sec><title>Model structure</title><p>Given the increased risk of developing TB in the first 2 to 5 years after TB
infection <sup>1</sup>, a Markov decision-analytic model was developed to
simulate a cohort of 10,000 healthcare workers over five annual cycles for TB
preventive treatment with 3HP. Then, four strategies for TB infection detection
were compared to the standard of care (TST), namely the QFT-Plus and three novel
skin tests: Diaskintest, C-TST, and Cy-TB. The model simulated the natural
history of TB infection, comparing the clinical outcomes and economic impacts of
the newer diagnostic technologies to the traditional TST. All analyses were
performed with TreeAge Pro Healthcare 2022 (<ext-link xlink:href="https://www.treeage.com/" ext-link-type="uri">https://www.treeage.com/</ext-link>).
The health states considered were (1) no TB infection; (2) TB infection; (3) no
TB infection, false positive test and not treated; (4) no TB infection, false
positive test and treated; (5) TB infection and not tested; (6) TB infection,
positive test and not treated; (7) TB infection, positive test and treated; (8)
TB; (9) cured TB; and (10) death <inline-supplementary-material xlink:href="1678-4464-csp-41-02-EN178623-s.pdf" id="d67e399" content-type="local-data">(Supplementary Material -
Figure S1</inline-supplementary-material>; <ext-link xlink:href="https://cadernos.ensp.fiocruz.br/static/arquivo/suppl-e00178623_5325.pdf" ext-link-type="uri">https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-e00178623_5325.pdf</ext-link>).
The model estimated the number of TB cases that occurred in each of the
strategies. The effectiveness measure was the number of TB cases avoided,
estimated by subtracting the number of cases observed in the strategy with the
reference test (TST) from those with the tests under evaluation (QFT-Plus and
TBST). The number needed to misdiagnose was also estimated, defined as the
number of patients who need to be tested in order for one to be misdiagnosed by
the test (either false positive or false negative results), considering a 0.37
TB infection prevalence (95% confidence interval [95%CI]: 0.17; 0.36) <xref rid="B18" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>,</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>. The incremental cost-effectiveness ratio (ICER) per TB case avoided was
estimated by subtracting the number of cases observed in the strategy with the
reference test (TST) from those with the tests under evaluation (QFT-Plus and
TBST).</p><p>The probability of progression from TB infection to TB without TB preventive
treatment was based on observed rates among healthcare workers for the first two
years after infection, then it considered the probability for the general
population <xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>.</p></sec><sec><title>Testing procedures and interpretation</title><p>This study considered five strategies, with four being based on skin tests, three
using the recombinant ESAT-6 and CFP-10 immunogens (Diaskintest, C-TST and
Cy-TB), and one - the current standard of care - using the tuberculin PPD Rt-23
(TST). By replacing PPD with <italic>M. tuberculosis</italic> specific antigens,
TBST combine the operational advantages of the TST with the specificity of
interferon-gamma release assays (IGRA). The fifth strategy employs the QFT-Plus
test, the only available IGRA in Brazil <xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref>.</p><p>All skin tests involve the intradermal application of the antigen on the volar
aspect of the forearm, following the Mantoux method in any healthcare facility
(usually by a trained nurse) <xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>. The test result is read 48 or 72 hours after application. The cutoff
point considered to define the result as positive was &#x02265; 5mm. If the reading is
lost, no further skin tests is conducted and the healthcare workers should be
retested after a 1-year interval.</p><p>QFT-Plus testing is conducted in the laboratory following the manufacturer&#x02019;s
instructions, using 1mL aliquots of whole blood, which can be obtained in the
healthcare facility and transported to the laboratory or directly in the
laboratory. If the result is indeterminate, the test is repeated once.
Conversion is defined when a negative test turns positive <xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>. Only healthcare workers with a negative initial test undergo subsequent
annual testing. When conversion of any TB infection test occurs, a chest
radiograph is performed and if negative, TB preventive treatment is recommended
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>.</p></sec><sec><title>Model parameters</title></sec><sec><title>Effectiveness data</title><p>Meta-analyses (<xref rid="t1" ref-type="table">Table 1</xref>) provided estimates
for clinical, epidemiological and tests accuracy parameters <xref rid="B21" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>,</sup>
<xref rid="B22" ref-type="bibr">
<sup>22</sup>
</xref>
<sup>,</sup>
<xref rid="B23" ref-type="bibr">
<sup>23</sup>
</xref>
<sup>,</sup>
<xref rid="B24" ref-type="bibr">
<sup>24</sup>
</xref>
<sup>,</sup>
<xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>
<sup>,</sup>
<xref rid="B26" ref-type="bibr">
<sup>26</sup>
</xref>
<sup>,</sup>
<xref rid="B27" ref-type="bibr">
<sup>27</sup>
</xref>
<sup>,</sup>
<xref rid="B28" ref-type="bibr">
<sup>28</sup>
</xref>
<sup>,</sup>
<xref rid="B29" ref-type="bibr">
<sup>29</sup>
</xref>
<sup>,</sup>
<xref rid="B30" ref-type="bibr">
<sup>30</sup>
</xref>. To estimate transition probabilities in the model, this study employed
different types of measurement statistics reported in the literature using the
method described by Gidwani &#x00026; Russell <xref rid="B31" ref-type="bibr">
<sup>31</sup>
</xref>
<inline-supplementary-material xlink:href="1678-4464-csp-41-02-EN178623-s.pdf" id="d67e540" content-type="local-data">(Supplementary
Material</inline-supplementary-material>; <ext-link xlink:href="https://cadernos.ensp.fiocruz.br/static/arquivo/suppl-e00178623_5325.pdf" ext-link-type="uri">https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-e00178623_5325.pdf</ext-link>).
Age-specific all-cause mortality rates were obtained from the 2022 Brazilian
National Mortality Table <xref rid="B32" ref-type="bibr">
<sup>32</sup>
</xref>.</p><p>
<table-wrap position="float" id="t1"><label>Table 1</label><caption><title>Model parameters: tests, treatment, status of infection, and
outcomes.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="2"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Model parameters</th><th align="center" rowspan="2" colspan="1">Base-case</th><th align="center" colspan="2" rowspan="1">Range </th><th align="center" rowspan="2" colspan="1">Source</th></tr><tr><th align="center" rowspan="1" colspan="1">Low</th><th align="center" rowspan="1" colspan="1">High</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Clinical and epidemiological parameters</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Incidence of TB
infection in healthcare workers (based TST) *</td><td align="center" rowspan="1" colspan="1">0.17</td><td align="center" rowspan="1" colspan="1">0.09</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">
<xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Probability of not
returning to TST treatment in healthcare workers</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">
<xref rid="B45" ref-type="bibr">
<sup>45</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Probability of
starting TB preventive treatment in healthcare workers
**</td><td align="center" rowspan="1" colspan="1">0.84</td><td align="center" rowspan="1" colspan="1">0.67</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">
<xref rid="B40" ref-type="bibr">
<sup>40</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Adherence to TB
preventive treatment with 3HP ***</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">0.80</td><td align="center" rowspan="1" colspan="1">0.83</td><td align="center" rowspan="1" colspan="1">
<xref rid="B28" ref-type="bibr">
<sup>28</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Efficacy of TB
preventive treatment with 3HP <sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">
<xref rid="B28" ref-type="bibr">
<sup>28</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Probability of adverse
events related to TB preventive treatment with 3HP
<sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1">0.19</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">
<xref rid="B29" ref-type="bibr">
<sup>29</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Probability of grade 3
or 4 adverse events related to TB preventive treatment with
3HP <sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">
<xref rid="B29" ref-type="bibr">
<sup>29</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Probability of adverse
events that lead to permanent drug discontinuation related
to TB preventive treatment with 3HP <sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">0.10</td><td align="center" rowspan="1" colspan="1">
<xref rid="B29" ref-type="bibr">
<sup>29</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Probability of death
by adverse events related to TB preventive treatment with
3HP <sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">0.0000004</td><td align="center" rowspan="1" colspan="1">0.0000</td><td align="center" rowspan="1" colspan="1">0.0010</td><td align="center" rowspan="1" colspan="1">
<xref rid="B29" ref-type="bibr">
<sup>29</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Progression from TB
infection to TB disease, no treatment (PPD-based TST &#x02265; 5mm)
<sup>###</sup>
</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">0.000</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1">
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Progression from TB
infection to TB disease with complete TB preventive
treatment with 3HP <sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">0.0004</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">
<xref rid="B28" ref-type="bibr">
<sup>28</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Test parameters</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">TST sensitivity
<sup>&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">0.77</td><td align="center" rowspan="1" colspan="1">0.71</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">
<xref rid="B42" ref-type="bibr">
<sup>42</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">TST specificity
<sup>&#x000a7;&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">0.46</td><td align="center" rowspan="1" colspan="1">0.73</td><td align="center" rowspan="1" colspan="1">
<xref rid="B42" ref-type="bibr">
<sup>42</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Diaskintest
sensitivity (&#x02265; 5mm) <sup>&#x000a7;&#x000a7;&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">0.91</td><td align="center" rowspan="1" colspan="1">0.81</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">
<xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Diaskintest
specificity (&#x0003c; 5mm) <sup>&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">
<xref rid="B26" ref-type="bibr">
<sup>26</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">C-TST skin test
sensitivity (&#x02265; 5mm) <sup>&#x02020;&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">0.86</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">0.89</td><td align="center" rowspan="1" colspan="1">
<xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">C-TST skin test
specificity (&#x0003c; 5mm) <sup>&#x02020;&#x02020;&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">
<xref rid="B26" ref-type="bibr">
<sup>26</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Cy-TB skin test
sensitivity (&#x02265; 5mm) <sup>&#x02021;</sup>
</td><td align="center" rowspan="1" colspan="1">0.74</td><td align="center" rowspan="1" colspan="1">0.70</td><td align="center" rowspan="1" colspan="1">0.78</td><td align="center" rowspan="1" colspan="1">
<xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Cy-TB skin test
specificity (&#x0003c; 5mm) <sup>&#x02021;&#x02021;</sup>
</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">0.94</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">
<xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">QFT-Plus sensitivity
<sup>&#x02021;&#x02021;&#x02021;</sup>
</td><td align="center" rowspan="1" colspan="1">0.91</td><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">0.94</td><td align="center" rowspan="1" colspan="1">
<xref rid="B30" ref-type="bibr">
<sup>30</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">QFT-Plus specificity
<sup>&#x0222b;</sup>
</td><td align="center" rowspan="1" colspan="1">0.97</td><td align="center" rowspan="1" colspan="1">0.95</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">
<xref rid="B30" ref-type="bibr">
<sup>30</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Probability of
indeterminate QFT-Plus <sup>&#x0222b;&#x0222b;</sup>
</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">
<xref rid="B30" ref-type="bibr">
<sup>30</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>3HP: three months of weekly doses of 900mg rifapentine and 900mg
isoniazid; IGRA: interferon-gamma release assays; PPD: purified
protein derivative; TB: tuberculosis; TST: tuberculin skin
test.</p></fn><fn id="TFN2"><p>* Incidence was defined as test conversion, including test
definitions of IGRA and TST positivity and conversion for the
studies included in this review. Data extracted from Figure 4
and Table S6 of the Apriani et al. <xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref>;</p></fn><fn id="TFN3"><p>** Data extracted from <xref rid="t2" ref-type="table">Table
2</xref> of the Alsdurf et al. <xref rid="B40" ref-type="bibr">
<sup>40</sup>
</xref>;</p></fn><fn id="TFN4"><p>*** The study population included adults and children with high
risk for developing TB disease. Data extracted from Analysis 4.4
of the Sharma et al. <xref rid="B28" ref-type="bibr">
<sup>28</sup>
</xref>;</p></fn><fn id="TFN5"><p>
<sup>#</sup> The study population included adults and children
with high risk for developing TB disease. The relative risk was
estimated by the authors for the risk of TB disease between the
two groups under assessment. Data extracted from Analysis 4.1 of
the Sharma et al. <xref rid="B28" ref-type="bibr">
<sup>28</sup>
</xref>;</p></fn><fn id="TFN6"><p>
<sup>##</sup> The study population included adults and children
that started TB preventive treatment. Data extracted from <xref rid="t3" ref-type="table">Table 3</xref>;</p></fn><fn id="TFN7"><p>
<sup>###</sup> Data extracted from <xref rid="t3" ref-type="table">Table 3</xref> and Table S24 of the Campbell et al.
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>;</p></fn><fn id="TFN8"><p>
<sup>&#x000a7;</sup> Sensitivity was estimated among adults and children
with TB disease. Data extracted from Figure 4 of the Pai et al.
<xref rid="B42" ref-type="bibr">
<sup>42</sup>
</xref>;</p></fn><fn id="TFN9"><p>
<sup>&#x000a7;&#x000a7;</sup> Specificity was estimated among subjects with
healthy low risk of TB infection with BCG vaccine scar. Summary
measure estimated by bivariate random effects model. Data
extracted from <xref rid="t1" ref-type="table">Table 1</xref>
and Supplementary <xref rid="t1" ref-type="table">Table 1</xref>
of the Pai et al. <xref rid="B42" ref-type="bibr">
<sup>42</sup>
</xref>;</p></fn><fn id="TFN10"><p>
<sup>&#x000a7;&#x000a7;&#x000a7;</sup> Sensitivity was estimated among adults and
children with microbiologically confirmed TB disease. Data
extracted from Supplementary Table S23 of the Krutikov et al.
<xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>;</p></fn><fn id="TFN11"><p>
<sup>&#x02020;</sup> Specificity was estimated among healthy adults and
children. Data extracted from Figure 4 and <xref rid="t1" ref-type="table">Table 1</xref> of the Starshinova
et al. <xref rid="B26" ref-type="bibr">
<sup>26</sup>
</xref>;</p></fn><fn id="TFN12"><p>
<sup>&#x02020;&#x02020;</sup> Sensitivity was estimated among adults and
children with microbiologically confirmed TB disease. Data
extracted from Figure 3 of the Krutikov et al. <xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>;</p></fn><fn id="TFN13"><p>
<sup>&#x02020;&#x02020;&#x02020;</sup> None of the systematic reviews evaluated
estimated the specificity of the C-TST test. As an alternative,
considering that both Diaskintest and C-TST are skin sensitivity
tests and use the recombinant <italic>Mycobacterium
tuberculosis</italic> antigens ESAT-6 and CFP-10, the
specificity of C-TST was considered equal to that of
Diaskintest;</p></fn><fn id="TFN14"><p>
<sup>&#x02021;</sup> Sensitivity was estimated among adults and children
with microbiologically confirmed TB disease. Data extracted from
Figure 4 of the Krutikov et al. <xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>;</p></fn><fn id="TFN15"><p>
<sup>&#x02021;&#x02021;</sup> Specificity was estimated among individuals
without active tuberculosis in studies performed in tuberculosis
low-incidence settings. Data extracted from Figure 5 of the
Krutikov et al. <xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>;</p></fn><fn id="TFN16"><p>
<sup>&#x02021;&#x02021;&#x02021;</sup> Sensitivity was estimated among patients with
diagnosis of TB disease confirmed by molecular methods, or
microbiological methods, or histopathology. Clinical diagnosis
would be acceptable if methods of diagnosis were clearly
described, and no TB infection test is incorporated in the
definition. Data extracted from <xref rid="t2" ref-type="table">Table 2</xref> and Supplementary Figure 2 of the Oh et al.
<xref rid="B30" ref-type="bibr">
<sup>30</sup>
</xref>;</p></fn><fn id="TFN17"><p>
<sup>&#x0222b;</sup> Specificity was estimated among adults with very
low risk for TB infection. Data extracted from <xref rid="t2" ref-type="table">Table 2</xref> and Supplementary
Figure 3 of the Oh et al. <xref rid="B30" ref-type="bibr">
<sup>30</sup>
</xref>;</p></fn><fn id="TFN18"><p>
<sup>&#x0222b;&#x0222b;</sup> Data extracted from <xref rid="t4" ref-type="table">Table 4</xref> of the Oh et al. <xref rid="B30" ref-type="bibr">
<sup>30</sup>
</xref> for studies that evaluated the sensitivity of the
QFT-Plus.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Costing data</title><p>Brazil boasts one of the largest universal public health systems (SUS), which
provides coverage for over 150 million people who rely exclusively on its
services. Given this, the national guideline for conducting economic evaluation
studies recommends adopting the perspective of the SUS as the purchaser of
services, thereby accounting for all costs covered by the public health system.
The costs of medical visits, chest radiograph, sputum smear, blood work-up,
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) dosage,
hospitalization, and death due to adverse events were obtained from the
Brazilian Hospital Information System (SIH, acronym in Portuguese) <xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>. The costs for isoniazid (300mg/pill), rifapentine (150mg/pill),
QFT-Plus (kit), and TST were informed by the PNCT (2024; personal
communication). The cost of treating TB with directly observed therapy (DOT)
were estimated by Steffen et al. <xref rid="B34" ref-type="bibr">
<sup>34</sup>
</xref>. A micro-costing analysis for conducting diagnostic tests for TB
infection was conducted and published elsewhere <xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>. <xref rid="t2" ref-type="table">Table 2</xref> and
<inline-supplementary-material xlink:href="1678-4464-csp-41-02-EN178623-s.pdf" id="d67e1202" content-type="local-data">Supplementary
Material</inline-supplementary-material> (<ext-link xlink:href="https://cadernos.ensp.fiocruz.br/static/arquivo/suppl-e00178623_5325.pdf" ext-link-type="uri">https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-e00178623_5325.pdf</ext-link>)
detail the sources of costs estimates. All values were adjusted for inflation by
the accumulated variation of the Brazilian Extended Consumer Price Index (IPCA,
acronym in Portuguese) for the period and converted into U.S. dollars (USD)
using the average annual rate according to Brazilian Central Bank (USD 1 = BRL
5.16) for 2022 <xref rid="B35" ref-type="bibr">
<sup>35</sup>
</xref>, as described by Turner et al. <xref rid="B36" ref-type="bibr">
<sup>36</sup>
</xref> (<xref rid="t2" ref-type="table">Tables 2</xref> and <xref rid="t3" ref-type="table">3</xref>, and <inline-supplementary-material xlink:href="1678-4464-csp-41-02-EN178623-s.pdf" id="d67e1225" content-type="local-data">Supplementary
Material</inline-supplementary-material>; <ext-link xlink:href="https://cadernos.ensp.fiocruz.br/static/arquivo/suppl-e00178623_5325.pdf" ext-link-type="uri">https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-e00178623_5325.pdf</ext-link>).</p><p>
<table-wrap position="float" id="t2"><label>Table 2</label><caption><title>Model parameters: costs (in USD, 2022).</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="3"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="3" colspan="1">Model parameters</th><th align="center" colspan="3" rowspan="1">Cost estimates (in USD) </th><th align="center" rowspan="1" colspan="1">Source</th></tr><tr><th align="center" rowspan="2" colspan="1">Base-case</th><th align="center" colspan="2" rowspan="1">Range </th><th align="left" rowspan="1" colspan="1">
</th></tr><tr><th align="center" rowspan="1" colspan="1">Low *</th><th align="center" rowspan="1" colspan="1">High **</th><th align="left" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Drugs and exams</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Isoniazid (300mg/pill)</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.07</td><td align="center" rowspan="1" colspan="1">***</td></tr><tr><td align="left" rowspan="1" colspan="1">Rifapentine (150mg/pill)</td><td align="center" rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">0.13</td><td align="center" rowspan="1" colspan="1">0.53</td><td align="center" rowspan="1" colspan="1">***</td></tr><tr><td align="left" rowspan="1" colspan="1">Rifapentine and isoniazid
(300mg/300mg/pill)</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">0.21</td><td align="center" rowspan="1" colspan="1">0.83</td><td align="center" rowspan="1" colspan="1">
<xref rid="B37" ref-type="bibr">
<sup>37</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood count</td><td align="center" rowspan="1" colspan="1">1.78</td><td align="center" rowspan="1" colspan="1">0.89</td><td align="center" rowspan="1" colspan="1">3.57</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum dosage AST</td><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">0.44</td><td align="center" rowspan="1" colspan="1">1.74</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum dosage ALT</td><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">0.44</td><td align="center" rowspan="1" colspan="1">1.74</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Medical visit</td><td align="center" rowspan="1" colspan="1">4.34</td><td align="center" rowspan="1" colspan="1">2.17</td><td align="center" rowspan="1" colspan="1">8.67</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Chest radiograph</td><td align="center" rowspan="1" colspan="1">4.12</td><td align="center" rowspan="1" colspan="1">2.06</td><td align="center" rowspan="1" colspan="1">8.24</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sputum smear</td><td align="center" rowspan="1" colspan="1">1.82</td><td align="center" rowspan="1" colspan="1">0.91</td><td align="center" rowspan="1" colspan="1">3.64</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TB infection diagnosis</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial medical visit (2 consultations)</td><td align="center" rowspan="1" colspan="1">8.67</td><td align="center" rowspan="1" colspan="1">4.34</td><td align="center" rowspan="1" colspan="1">17.35</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Chest radiograph</td><td align="center" rowspan="1" colspan="1">4.12</td><td align="center" rowspan="1" colspan="1">2.06</td><td align="center" rowspan="1" colspan="1">8.24</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">12.79</td><td align="center" rowspan="1" colspan="1">6.40</td><td align="center" rowspan="1" colspan="1">25.59</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">TB disease diagnosis</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial medical visit (2 consultations)</td><td align="center" rowspan="1" colspan="1">8.67</td><td align="center" rowspan="1" colspan="1">4.34</td><td align="center" rowspan="1" colspan="1">17.35</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Chest radiograph</td><td align="center" rowspan="1" colspan="1">4.12</td><td align="center" rowspan="1" colspan="1">2.06</td><td align="center" rowspan="1" colspan="1">8.24</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sputum smear</td><td align="center" rowspan="1" colspan="1">1.82</td><td align="center" rowspan="1" colspan="1">0.91</td><td align="center" rowspan="1" colspan="1">3.64</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">14.62</td><td align="center" rowspan="1" colspan="1">7.31</td><td align="center" rowspan="1" colspan="1">29.23</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">TB disease treatment with DOT <sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">829.08</td><td align="center" rowspan="1" colspan="1">414.54</td><td align="center" rowspan="1" colspan="1">1,658.17</td><td align="center" rowspan="1" colspan="1">
<xref rid="B34" ref-type="bibr">
<sup>34</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TB infection treatment with isoniazid
(900mg/week) plus rifapentine (900mg/week) for 2 months
(GDF)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Rifapentine and isoniazid (900mg/900mg/week) (2
months/8 doses/24 pills)</td><td align="center" rowspan="1" colspan="1">10.00</td><td align="center" rowspan="1" colspan="1">5.00</td><td align="center" rowspan="1" colspan="1">20.00</td><td align="center" rowspan="1" colspan="1">
<xref rid="B37" ref-type="bibr">
<sup>37</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Medical consultation (1 consultation)</td><td align="center" rowspan="1" colspan="1">4.34</td><td align="center" rowspan="1" colspan="1">2.17</td><td align="center" rowspan="1" colspan="1">8.67</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">14.34</td><td align="center" rowspan="1" colspan="1">7.17</td><td align="center" rowspan="1" colspan="1">28.67</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">TB infection treatment with isoniazid
(900mg/week) plus rifapentine (900mg/week) for 3 months
(GDF)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Rifapentine and isoniazid (900mg/900mg/week) (3
months/12 doses/36 pills)</td><td align="center" rowspan="1" colspan="1">15.00</td><td align="center" rowspan="1" colspan="1">7.50</td><td align="center" rowspan="1" colspan="1">30.00</td><td align="center" rowspan="1" colspan="1">
<xref rid="B37" ref-type="bibr">
<sup>37</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Medical consultation (2 consultations)</td><td align="center" rowspan="1" colspan="1">8.67</td><td align="center" rowspan="1" colspan="1">4.34</td><td align="center" rowspan="1" colspan="1">17.35</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">23.67</td><td align="center" rowspan="1" colspan="1">11.84</td><td align="center" rowspan="1" colspan="1">47.35</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Costs of grade 3 or 4 adverse events related to
TB preventive treatment with 3HP</td><td align="center" rowspan="1" colspan="1">86.45</td><td align="center" rowspan="1" colspan="1">43.23</td><td align="center" rowspan="1" colspan="1">172.90</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events follow-up</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Medical visit (3 consultations)</td><td align="center" rowspan="1" colspan="1">13.01</td><td align="center" rowspan="1" colspan="1">6.51</td><td align="center" rowspan="1" colspan="1">26.02</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood count (2 exams)</td><td align="center" rowspan="1" colspan="1">3.57</td><td align="center" rowspan="1" colspan="1">1.78</td><td align="center" rowspan="1" colspan="1">7.13</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum dosage AST (2 exams)</td><td align="center" rowspan="1" colspan="1">1.74</td><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">3.49</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum dosage ALT (2 exams)</td><td align="center" rowspan="1" colspan="1">1.74</td><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">3.49</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">20.06</td><td align="center" rowspan="1" colspan="1">10.03</td><td align="center" rowspan="1" colspan="1">40.13</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Diagnostic tests</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">QFT Plus</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Human resources
<sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">1.73</td><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">3.46</td><td align="center" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">QFT-Plus test kit
<sup>###</sup>
</td><td align="center" rowspan="1" colspan="1">17.68</td><td align="center" rowspan="1" colspan="1">8.84</td><td align="center" rowspan="1" colspan="1">35.36</td><td align="center" rowspan="1" colspan="1">***</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Consumables
<sup>&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">1.40</td><td align="center" rowspan="1" colspan="1">0.70</td><td align="center" rowspan="1" colspan="1">2.80</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Equipment
<sup>&#x000a7;&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">0.83</td><td align="center" rowspan="1" colspan="1">0.41</td><td align="center" rowspan="1" colspan="1">1.65</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">21.64</td><td align="center" rowspan="1" colspan="1">10.82</td><td align="center" rowspan="1" colspan="1">43.27</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">TST PPD Rt-23 (2UT/1.5mL)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Human resources
<sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">1.64</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">3.28</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Consumables
<sup>&#x000a7;&#x000a7;&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">1.01</td><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">2.02</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Equipment <sup>&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">PPD Rt-23
(2UT/1.5mL)</td><td align="center" rowspan="1" colspan="1">0.93</td><td align="center" rowspan="1" colspan="1">0.47</td><td align="center" rowspan="1" colspan="1">1.86</td><td align="center" rowspan="1" colspan="1">***</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">3.62</td><td align="center" rowspan="1" colspan="1">1.81</td><td align="center" rowspan="1" colspan="1">7.24</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Diaskintest</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Human resources
<sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">1.64</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">3.28</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Consumables
<sup>&#x000a7;&#x000a7;&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">1.01</td><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">2.02</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Equipment <sup>&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Diaskintest</td><td align="center" rowspan="1" colspan="1">1.43</td><td align="center" rowspan="1" colspan="1">0.72</td><td align="center" rowspan="1" colspan="1">2.86</td><td align="center" rowspan="1" colspan="1">
<sup>&#x02020;&#x02020;</sup>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">4.12</td><td align="center" rowspan="1" colspan="1">2.06</td><td align="center" rowspan="1" colspan="1">8.24</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">C-TST</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Human resources
<sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">1.64</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">3.28</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Consumables
<sup>&#x000a7;&#x000a7;&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">1.01</td><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">2.02</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Equipment <sup>&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">C-TST skin test</td><td align="center" rowspan="1" colspan="1">6.09</td><td align="center" rowspan="1" colspan="1">3.05</td><td align="center" rowspan="1" colspan="1">12.18</td><td align="center" rowspan="1" colspan="1">
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">8.78</td><td align="center" rowspan="1" colspan="1">4.39</td><td align="center" rowspan="1" colspan="1">17.56</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cy-TB</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Human resources
<sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">1.64</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">3.28</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Consumables
<sup>&#x000a7;&#x000a7;&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">1.01</td><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">2.02</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Equipment <sup>&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Cy-TB skin test</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">0.50</td><td align="center" rowspan="1" colspan="1">2.00</td><td align="center" rowspan="1" colspan="1">
<sup>&#x02020;&#x02020;</sup>
</td></tr><tr><td align="left" style="text-indent:12px" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">3.69</td><td align="center" rowspan="1" colspan="1">1.84</td><td align="center" rowspan="1" colspan="1">7.38</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cost of death for adverse events related to TB
preventive treatment with 3HP</td><td align="center" rowspan="1" colspan="1">441.20</td><td align="center" rowspan="1" colspan="1">220.60</td><td align="center" rowspan="1" colspan="1">882.40</td><td align="center" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Discount rate</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.10</td><td align="center" rowspan="1" colspan="1">
<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN19"><p>3HP: three months of weekly doses of 900mg rifapentine and 900mg
isoniazid; ALT: alanine aminotransferase; AST: aspartate
aminotransferase; DOT: directly observed therapy; GDF: Global
Drug Facility; PPD: purified protein derivative; TB:
tuberculosis; TBST: tuberculosis antigen-based skin tests; TST:
tuberculin skin test.</p></fn><fn id="TFN20"><p>* The lower limit was 50% of the cost estimate value;</p></fn><fn id="TFN21"><p>** The upper limit was double the cost estimate value;</p></fn><fn id="TFN22"><p>*** The costs for isoniazid (300mg/pill), rifapentine
(150mg/pill), QFT-Plus (kit), and TST were identified from
personal communication with the Brazilian National Tuberculosis
Control Program;</p></fn><fn id="TFN23"><p>
<sup>#</sup> DOT costs based on five weekly visits during the
intensive phase (first 2 months) and twice weekly during the
continuation phase (remaining 4 months);</p></fn><fn id="TFN24"><p>
<sup>##</sup> Nursing staff time (for TBST and TST only),
laboratory technician time (for QFT-Plus only);</p></fn><fn id="TFN25"><p>
<sup>###</sup> QFT-Plus test kit included blood collection
tubes, microplates, and reagents for the enzyme-linked
immunosorbent assay;</p></fn><fn id="TFN26"><p>
<sup>&#x000a7;</sup> Gloves, needles, tourniquet, cotton, alcohol, box
for syringes, Eppendorf, cryotube, color-coded insert (red and
blue), DNA Free Pyrogen (200&#x003bc;L - sterile and with filter), and
D1000 Diamond Tipack 100-1000&#x003bc;L (sterile and with filter);</p></fn><fn id="TFN27"><p>
<sup>&#x000a7;&#x000a7;</sup> Incubator, centrifuge, microplate washer,
microplate reader, computer, and printer;</p></fn><fn id="TFN28"><p>
<sup>&#x000a7;&#x000a7;&#x000a7;</sup> Gloves, cotton, alcohol, syringes with needles,
box for syringes, thermal box, and ice bag;</p></fn><fn id="TFN29"><p>
<sup>&#x02020;</sup> Fridge, thermometer with alarm, and millimeter
ruler;</p></fn><fn id="TFN30"><p>
<sup>&#x02020;&#x02020;</sup> The costs of the Cy-TB test and Diaskintest were
identified from personal communication with the
manufacturers.</p></fn></table-wrap-foot></table-wrap>
</p><p>The complete TB preventive treatment costs included 12 weekly doses of
rifapentine (900mg) and isoniazid (900mg) and two medical monitoring visits; 3HP
was self-administered <xref rid="B9" ref-type="bibr">
<sup>9</sup>
</xref>. Brazil does not acquire consumables from the Global Drug Facility
(GDF); thus, information were obtained from the Brazilian Ministry of Health,
and the GDF value considered the combined weekly dose of 3HP in the sensitivity
analysis <xref rid="B37" ref-type="bibr">
<sup>37</sup>
</xref>.</p><p>Partial treatment costs for TB infection were considered for those who developed
severe adverse events and did not complete TB preventive treatment. The
incomplete TB preventive treatment included costs with two months of weekly
doses of rifapentine (900mg) and isoniazid (900mg) and one medical
consultation.</p><p>Cases of severe adverse events with 3HP incurred in hospitalization costs, valued
by the code <italic>Treatment of Complications of Surgical or Clinical
Procedures</italic> from the SIH table, with a 35% increase in values
related to professional care in hospitals considered as type II urgency <xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>.</p><p>In cases of adverse events that evolved to death, costs equivalent to two daily
hospitalizations to the intensive care unit were included <xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>. For those who survived, the monitoring costs of severe adverse events
were also included, encompassing three doctor visits, two blood count tests, and
two tests for AST and ALT.</p></sec><sec><title>Sensitivity analyses</title><p>One-way sensitivity analysis was conducted on all model inputs, using the 95%CI
range of transition probabilities. For the cost parameters, the lower limit of
the range was half the price and the upper limit, twice the price <xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>. A probabilistic sensitivity analysis was also performed in a Monte
Carlo simulation with 10,000 iterations (<xref rid="t3" ref-type="table">Table
3</xref>). It was assumed that the uncertainty in clinical probabilities and
accuracies followed a beta distribution, with the standard deviation (SD)
estimated based on data extracted from systematic literature reviews
<inline-supplementary-material xlink:href="1678-4464-csp-41-02-EN178623-s.pdf" id="d67e2361" content-type="local-data">(Supplementary
Material</inline-supplementary-material>; <ext-link xlink:href="https://cadernos.ensp.fiocruz.br/static/arquivo/suppl-e00178623_5325.pdf" ext-link-type="uri">https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-e00178623_5325.pdf</ext-link>).
A gamma distribution was assumed for costs, with the SD equal to 10% of the
original value. The generated distributions of costs, TB cases avoiding
diagnosis of TB infection and its preventive treatment, and ICER are shown using
median and 95% uncertainty ranges (UR).</p><p>
<table-wrap position="float" id="t3"><label>Table 3</label><caption><title>General model parameters and distributions.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Model parameters</th><th align="center" rowspan="1" colspan="1">Deterministic mean</th><th align="center" rowspan="1" colspan="1">PSA probability distribution</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1">Source</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Clinical and epidemiological parameters</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Incidence of TB infection in healthcare workers
treated with TST</td><td align="center" rowspan="1" colspan="1">0.17</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1">
<sup>3</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Probability of not returning to TST treatment
in healthcare workers</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">
<sup>43</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Probability of starting TB preventive treatment
in healthcare workers</td><td align="center" rowspan="1" colspan="1">0.84</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.012</td><td align="center" rowspan="1" colspan="1">
<sup>21</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Adherence to TB preventive treatment with
3HP</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">
<sup>28</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Efficacy of TB preventive treatment with
3HP</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.0006</td><td align="center" rowspan="1" colspan="1">
<sup>28</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Probability of adverse events related to TB
preventive treatment with 3HP</td><td align="center" rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">
<sup>29</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Probability of grade 3 or 4 adverse events
related to TB preventive treatment with 3HP</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">
<sup>29</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Probability of adverse events that lead to
permanent drug discontinuation related to TB preventive
treatment with 3HP</td><td align="center" rowspan="1" colspan="1">0.080</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">
<sup>29</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Probability of death by adverse events related
to TB preventive treatment with 3HP</td><td align="center" rowspan="1" colspan="1">0.0000004</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.000005</td><td align="center" rowspan="1" colspan="1">
<sup>29</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Progression from TB infection to TB disease, no
treatment (based TST &#x02265; 5mm)</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">
<sup>20</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Progression from TB infection to TB disease
with complete TB preventive treatment with 3HP</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">
<sup>28</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TST sensitivity (&#x02265; 5mm)</td><td align="center" rowspan="1" colspan="1">0.77</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.012</td><td align="center" rowspan="1" colspan="1">
<sup>41</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TST specificity (&#x0003c; 5mm)</td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.020</td><td align="center" rowspan="1" colspan="1">
<sup>41</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Diaskintest sensitivity (&#x02265; 5mm)</td><td align="center" rowspan="1" colspan="1">0.91</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.034</td><td align="center" rowspan="1" colspan="1">
<sup>25</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Diaskintest specificity (&#x0003c; 5mm)</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.00007</td><td align="center" rowspan="1" colspan="1">
<sup>26</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">C-TST test sensitivity (&#x02265; 5mm)</td><td align="center" rowspan="1" colspan="1">0.86</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.016</td><td align="center" rowspan="1" colspan="1">
<sup>25</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">C-TST test specificity (&#x0003c; 5mm)</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.00007</td><td align="center" rowspan="1" colspan="1">
<sup>26</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">QFT-Plus sensitivity</td><td align="center" rowspan="1" colspan="1">0.91</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.011</td><td align="center" rowspan="1" colspan="1">
<sup>30</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">QFT-Plus specificity</td><td align="center" rowspan="1" colspan="1">0.97</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.009</td><td align="center" rowspan="1" colspan="1">
<sup>30</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Probability of indeterminate QFT-Plus</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">
<sup>30</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cy-TB test sensitivity (&#x02265; 5mm)</td><td align="center" rowspan="1" colspan="1">0.74</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.020</td><td align="center" rowspan="1" colspan="1">
<sup>25</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cy-TB test specificity (&#x0003c; 5mm)</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">
<sup>25</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cost estimates (in USD, 2022)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">TB infection diagnosis</td><td align="center" rowspan="1" colspan="1">12.79</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">2.56</td><td align="center" rowspan="1" colspan="1">
<sup>33</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TB disease diagnosis</td><td align="center" rowspan="1" colspan="1">14.62</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">2.92</td><td align="center" rowspan="1" colspan="1">
<sup>33</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TB disease treatment with DOT *</td><td align="center" rowspan="1" colspan="1">829.08</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">165.82</td><td align="center" rowspan="1" colspan="1">
<sup>34</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TB preventive treatment with rifapentine
(900mg/week) plus isoniazid (900mg/week) for 2 months</td><td align="center" rowspan="1" colspan="1">17.83</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">3.57</td><td align="center" rowspan="1" colspan="1">
<sup>11</sup> **</td></tr><tr><td align="left" rowspan="1" colspan="1">TB preventive treatment with 3HP</td><td align="center" rowspan="1" colspan="1">28.91</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">5.78</td><td align="center" rowspan="1" colspan="1">
<sup>11</sup> **</td></tr><tr><td align="left" rowspan="1" colspan="1">TB preventive treatment with rifapentine
(900mg/week) plus isoniazid (900mg/week) for 2 months
(GDF)</td><td align="center" rowspan="1" colspan="1">14.34</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">2.87</td><td align="center" rowspan="1" colspan="1">
<sup>11, 40</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TB preventive treatment with 3HP (GDF)</td><td align="center" rowspan="1" colspan="1">23.67</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">4.73</td><td align="center" rowspan="1" colspan="1">
<sup>11, 40</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment for grade 3 or 4 adverse events
related to TB preventive treatment with 3HP</td><td align="center" rowspan="1" colspan="1">86.45</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">17.29</td><td align="center" rowspan="1" colspan="1">
<sup>33</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events follow-up</td><td align="center" rowspan="1" colspan="1">20.06</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">4.01</td><td align="center" rowspan="1" colspan="1">
<sup>33</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">QFT Plus test ***</td><td align="center" rowspan="1" colspan="1">17.68</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">3.54</td><td align="center" rowspan="1" colspan="1">**</td></tr><tr><td align="left" rowspan="1" colspan="1">TST PPD Rt-23 (2UT/1.5mL)</td><td align="center" rowspan="1" colspan="1">0.93</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">0.19</td><td align="center" rowspan="1" colspan="1">**</td></tr><tr><td align="left" rowspan="1" colspan="1">Diaskintest</td><td align="center" rowspan="1" colspan="1">1.43</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">0.29</td><td align="center" rowspan="1" colspan="1">
<sup>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">C-TST skin test</td><td align="center" rowspan="1" colspan="1">6.09</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">1.22</td><td align="center" rowspan="1" colspan="1">
<sup>12</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cy-TB skin test</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">0.20</td><td align="center" rowspan="1" colspan="1">
<sup>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Human resources for TST and TBST <sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">1.64</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">
<sup>11</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Consumables for TST and TBST <sup>###</sup>
</td><td align="center" rowspan="1" colspan="1">1.01</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">0.20</td><td align="center" rowspan="1" colspan="1">
<sup>11</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Equipment for TST and TBST <sup>&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">
<sup>11</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Human resources for QFT-Plus <sup>##</sup>
</td><td align="center" rowspan="1" colspan="1">1.73</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">0.35</td><td align="center" rowspan="1" colspan="1">
<sup>11</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Consumables for QFT-Plus <sup>&#x000a7;&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">1.40</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">0.28</td><td align="center" rowspan="1" colspan="1">
<sup>11</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Equipment for QFT-Plus <sup>&#x000a7;&#x000a7;&#x000a7;</sup>
</td><td align="center" rowspan="1" colspan="1">0.83</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">0.17</td><td align="center" rowspan="1" colspan="1">
<sup>11</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cost of death for adverse events</td><td align="center" rowspan="1" colspan="1">441.20</td><td align="center" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">88.24</td><td align="center" rowspan="1" colspan="1">
<sup>33</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Discount rate</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">Triangular</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">
<sup>1</sup>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN31"><p>3HP: three months of weekly doses of 900mg rifapentine and 900mg
isoniazid; DOT: directly observed therapy; GDF: Global Drug
Facility; PPD: purified protein derivative; PSA: probabilistic
sensitivity analysis; SD: standard deviation; TB: tuberculosis;
TBST: tuberculosis antigen-based skin tests; TST: tuberculin
skin test.</p></fn><fn id="TFN32"><p>* DOT costs based on 5 weekly visits during the intensive phase
(first 2 months) and twice weekly during the continuation phase
(remaining 4 months);</p></fn><fn id="TFN33"><p>** The costs for isoniazid (300mg/pill), rifapentine
(150mg/pill), QFT-Plus (kit), and TST were identified from
personal communication with the Brazilian National Tuberculosis
Control Program;</p></fn><fn id="TFN34"><p>*** QFT-Plus test kit included blood collection tubes,
microplates, and reagents for the enzyme-linked immunosorbent
assay;</p></fn><fn id="TFN35"><p>
<sup>#</sup> The costs of the Cy-TB test and Diaskintest were
identified from personal communication with manufacturers;</p></fn><fn id="TFN36"><p>
<sup>##</sup> Nursing staff time (for TBST and TST only),
laboratory technician time (for QFT-Plus only);</p></fn><fn id="TFN37"><p>
<sup>###</sup> Gloves, cotton, alcohol, syringes with needles,
box for syringes, thermal box, and ice bag;</p></fn><fn id="TFN38"><p>
<sup>&#x000a7;</sup> Fridge, thermometer with alarm, and millimeter
ruler;</p></fn><fn id="TFN39"><p>
<sup>&#x000a7;&#x000a7;</sup> Gloves, needles, tourniquet, cotton, alcohol, box
for syringes, Eppendorf, cryotube, color-coded insert (red and
blue), DNA Free Pyrogen (200&#x003bc;L - sterile and with filter), and
D1000 Diamond Tipack 100-1000&#x003bc;L (sterile and with filter);</p></fn><fn id="TFN40"><p>
<sup>&#x000a7;&#x000a7;&#x000a7;</sup> Incubator, centrifuge, microplate washer,
microplate reader, computer, and printer.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Model assumptions</title><p>The cohort undergoes standard procedures for healthcare workers, as prescribed by
the Brazilian national guidelines. Several simplifying assumptions were
incorporated into the model: (1) all healthcare workers were asymptomatic and
without TB; (2) no one was HIV-infected; (3) healthcare workers with a positive
test result underwent chest radiography and physical examination to exclude TB;
(4) chest radiography and symptom screening are 100% accurate in ruling out TB;
(5) individuals with a second indeterminate result on the QFT-Plus test had the
same risk of developing TB as those with a negative result; (6) nonadherence to
treatment due to adverse events occurred in the first two months and conferred
no partial protection; (7) all individuals with TB accepted treatment; (8)
patients who completed TB treatment were considered cured; (9) all TB and TB
infection cases are sensitive to antituberculosis drugs; (10) people who did not
adhere to TB preventive treatment did not develop adverse events; (11) the death
of an healthcare workers from other causes had no financial impact on the
Brazilian Ministry of Health; and (12) our assessment considered the stability
of newer recombinant reagents to be comparable to that of PPD Rt-23.</p></sec><sec><title>Willingness-to-pay threshold</title><p>In Brazil, the government-established threshold for cost-effectiveness is USD
7,752 per quality-adjusted life-year (QALY) gained <xref rid="B38" ref-type="bibr">
<sup>38</sup>
</xref>. Due to the lack of a threshold reference for case avoidance in Brazil,
the QALY threshold was adopted as a reference, which has been the metric used
for the incorporation of technologies into the SUS. To assess the
cost-effectiveness of the intervention, this threshold was employed for each TB
case prevented. Then, a cost-effectiveness acceptability curve was constructed,
which illustrates the probability of the intervention being deemed
cost-effective across a range of willingness-to-pay threshold values.</p></sec><sec><title>Price threshold analysis</title><p>Price threshold analysis was conducted to determine the maximum price at which
the strategy incorporating QFT-Plus would be considered cost-effective. This
analysis was carried out probabilistically, enabling the assessment of
uncertainties in the model parameters and their influence on the
cost-effectiveness of the intervention.</p><p>This cost-effectiveness report followed the <italic>Consolidated Health Economic
Evaluation Reporting Standards 2022</italic> (CHEERS 2022) statement <xref rid="B39" ref-type="bibr">
<sup>39</sup>
</xref>.</p></sec></sec><sec sec-type="results"><title>Results</title><p>
<xref rid="t4" ref-type="table">Table 4</xref> presents the projected costs and
health outcomes of simulated strategies. The SUS costs for screening 10,000
healthcare workers over a 5-year period, including screening and treatment costs for
both TB infection using weekly 3HP doses and TB treatment with DOT, were: USD
298,236 (95%UR: 251,196; 353,603) for Diaskintest; USD 286,640 (95%UR: 241,310;
340,003) for Cy-TB test; USD 434,984 (95%UR: 357,541; 525,148) for C-TST test; USD
334,619 (95%UR: 273,173; 409,566) for TST; and USD 801,727 (95%UR: 620,926;
1,028,999) for QFT-Plus. Compared to TST, the Diaskintest and Cy-TB strategies were
the most cost saving for TB infection diagnosis (USD 7,239 and USD 62,388 per TB
case averted, respectively) (<inline-supplementary-material xlink:href="1678-4464-csp-41-02-EN178623-s.pdf" id="d67e3071" content-type="local-data">Supplementary Material - Figure
S2 and Table S4</inline-supplementary-material>; <ext-link xlink:href="https://cadernos.ensp.fiocruz.br/static/arquivo/suppl-e00178623_5325.pdf" ext-link-type="uri">https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-e00178623_5325.pdf</ext-link>).
Despite QFT-Plus demonstrating slightly higher effectiveness compared to Diaskintest
and Cy-TB, the incremental cost of using QFT-Plus was USD 84,038 per TB case averted
(<xref rid="t4" ref-type="table">Table 4</xref>).</p><p>
<table-wrap position="float" id="t4"><label>Table 4</label><caption><title>Strategy rankings - all referencing common baseline (in USD,
2022).</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="2"/><col span="1"/><col span="1"/><col span="2"/><col span="1"/><col span="1"/><col span="2"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Strategy</th><th align="center" rowspan="2" colspan="1">Cost per 10,000 healthcare
workers</th><th align="center" colspan="2" rowspan="1">95%UR </th><th align="center" rowspan="1" colspan="1">Incremental cost per 10,000 healthcare
workers</th><th align="center" rowspan="1" colspan="1">TB disease cases</th><th align="center" colspan="2" rowspan="1">95%UR </th><th align="center" rowspan="1" colspan="1">TB disease cases averted</th><th align="center" rowspan="1" colspan="1">ICER</th><th align="center" colspan="2" rowspan="1">95%UR </th></tr><tr><th align="center" rowspan="1" colspan="1">Low</th><th align="center" rowspan="1" colspan="1">High</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">Low</th><th align="center" rowspan="1" colspan="1">High</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">Low</th><th align="center" rowspan="1" colspan="1">High</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TST</td><td align="center" rowspan="1" colspan="1">334,619</td><td align="center" rowspan="1" colspan="1">273,173</td><td align="center" rowspan="1" colspan="1">409,566</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Diaskintest</td><td align="center" rowspan="1" colspan="1">298,236</td><td align="center" rowspan="1" colspan="1">251,196</td><td align="center" rowspan="1" colspan="1">353,603</td><td align="center" rowspan="1" colspan="1">-36,383</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">-7,239</td><td align="center" rowspan="1" colspan="1">-4,229</td><td align="center" rowspan="1" colspan="1">-12,885</td></tr><tr><td align="left" rowspan="1" colspan="1">C-TST</td><td align="center" rowspan="1" colspan="1">434,984</td><td align="center" rowspan="1" colspan="1">357,541</td><td align="center" rowspan="1" colspan="1">525,148</td><td align="center" rowspan="1" colspan="1">100,365</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">25,917</td><td align="center" rowspan="1" colspan="1">22,385</td><td align="center" rowspan="1" colspan="1">29,663</td></tr><tr><td align="left" rowspan="1" colspan="1">Cy-TB</td><td align="center" rowspan="1" colspan="1">286,640</td><td align="center" rowspan="1" colspan="1">241,310</td><td align="center" rowspan="1" colspan="1">340,003</td><td align="center" rowspan="1" colspan="1">-47,979</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">-62,388</td><td align="center" rowspan="1" colspan="1">-31,709</td><td align="center" rowspan="1" colspan="1">-153,995</td></tr><tr><td align="left" rowspan="1" colspan="1">QFT-Plus</td><td align="center" rowspan="1" colspan="1">801,727</td><td align="center" rowspan="1" colspan="1">620,926</td><td align="center" rowspan="1" colspan="1">1,028,999</td><td align="center" rowspan="1" colspan="1">467,108</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">84,038</td><td align="center" rowspan="1" colspan="1">66,875</td><td align="center" rowspan="1" colspan="1">105,846</td></tr></tbody></table><table-wrap-foot><fn id="TFN41"><p>ICER: incremental cost-effectiveness ratio; TB: tuberculosis; TST:
tuberculin skin test; UR: uncertainty ranges.</p></fn></table-wrap-foot></table-wrap>
</p><p>With regards to number needed to misdiagnose, 29, 92, 155, 191, and 217 tests are
necessary for 10 healthcare workers to be misdiagnosed by the TST, Cy-TB, C-TST,
QFT-Plus, and Diaskintest, respectively.</p><p>Monte Carlo simulations showed that, at a willingness to pay threshold of USD 7,752
per TB case averted and considering all screening strategies simultaneously, the
Diaskintest showed the highest net benefit in 92.9%. The Cy-TB strategy presented
the highest net benefit in 7.1%. Cost-effectiveness acceptability curve,
illustrating the proportion of simulations in which each strategy holds the highest
net benefit at different willingness to pay thresholds is provided in
<inline-supplementary-material xlink:href="1678-4464-csp-41-02-EN178623-s.pdf" id="d67e3276" content-type="local-data">Supplementary
Material</inline-supplementary-material> (Figure S3; <ext-link xlink:href="https://cadernos.ensp.fiocruz.br/static/arquivo/suppl-e00178623_5325.pdf" ext-link-type="uri">https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-e00178623_5325.pdf</ext-link>).</p><p>One-way sensitivity analyses demonstrated that the incremental cost-effectiveness of
TB infection screening strategies among healthcare workers was most sensitive to
estimated TB infection incidence in healthcare workers (TST), the cost of TB
preventive treatment, the cost of excluding TB, and the cost of Diaskintest
(<inline-supplementary-material xlink:href="1678-4464-csp-41-02-EN178623-s.pdf" id="d67e3284" content-type="local-data">Supplementary
Material</inline-supplementary-material> - Table S4 and Figure S4; <ext-link xlink:href="https://cadernos.ensp.fiocruz.br/static/arquivo/suppl-e00178623_5325.pdf" ext-link-type="uri">https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-e00178623_5325.pdf</ext-link>).
The cost-effectiveness estimates for Cy-TB strategy was also sensitive to TST
specificity (<inline-supplementary-material xlink:href="1678-4464-csp-41-02-EN178623-s.pdf" id="d67e3290" content-type="local-data">Supplementary
Material</inline-supplementary-material> - Table S4 and Figure S4; <ext-link xlink:href="https://cadernos.ensp.fiocruz.br/static/arquivo/suppl-e00178623_5325.pdf" ext-link-type="uri">https://cadernos.ensp.fiocruz.br/static//arquivo/suppl-e00178623_5325.pdf</ext-link>).</p><p>Considering the GDF value for the combined weekly dose of 3HP, a cost reduction is
observed for all screening strategies: USD 281,689 for Diaskintest; USD 270,768 for
Cy-TB; USD 418,605 for C-TST test; USD 308,507 for TST; and USD 784,573 for
QFT-Plus. When compared to TST, assuming a higher probability of progression from TB
infection to TB in the first two years after infection (0.015) in healthcare
workers, the Diaskintest strategy remains the most cost saving for TB infection
diagnosis, with savings of USD 5,244 per TB case averted.</p><p>Price threshold analysis, at a willingness-to-pay threshold of USD 7,752 per TB case
averted, showed that for the QFT-Plus strategy to be more cost-effective when
compared to Diaskintest, it should cost USD 0.16. On the other hand, for the
screening strategy with QFT-Plus to be more cost-effective when compared to that of
Cy-TB, the QFT-Plus test should cost USD 0.91.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>In this cost-effectiveness model, we compared the Diaskintest screening strategy with
the TST for Brazilian healthcare workers. The Diaskintest test was the most cost
saving, followed by the Cy-TB test. The QFT-Plus test was more costly with slightly
higher effectiveness. Diaskintest has also been shown to be cost saving in Brazilian
PLWH <xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>. The main reason for these findings is the costs of tests. All
ESAT-6/CFP-10-based tests, whether in vivo (TBST) or ex vivo (QFT-Plus), exhibit
similar accuracy <xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>. Consequently, their cost-effectiveness is based primarily on their costs.
The QFT-Plus (and other World Health Organization [WHO]-approved IGRA tests)
requires equipment, laboratory infrastructure, sample transportation from health
facilities to the laboratory, and labor-intensive processes. Consumables (mainly the
test kits) also contribute to the cost. In contrast, while the tuberculin unit is
expensive, the test requires less labor (approximately 6.5 minutes total in low-and
middle-income countries) <xref rid="B40" ref-type="bibr">
<sup>40</sup>
</xref> and can be conducted in any clinic with a refrigerator for storing vials and
properly trained personnel.</p><p>The WHO recommends TB infection tests for high-risk populations, such as PLWH and
household contacts with bacteriologically confirmed pulmonary TB (regardless of age
or HIV status) <xref rid="B41" ref-type="bibr">
<sup>41</sup>
</xref>. In Brazil, TB infection tests are mandatory for most individuals undergoing
TB preventive treatment <xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref>. Our findings support the Brazilian recommendation and suggest that
Diaskintest or another specific test with similar costs should be incorporated.
However, there is currently more evidence on the safety and accuracy of the Cy-TB
test, and decisions to incorporate new technologies into the health system follows a
multicriteria logic. As for QFT-Plus to be more cost-effective in this population,
it should cost less than USD 1.</p><p>While both Diaskintest and Cy-TB exhibited cost-saving advantages over alternative
interventions, their overall savings are contingent upon various factors, including
final costs, which are subject to fluctuations in exchange rates and the
optimization of reagent supply chains. Factors such as storage requirements, dosage
per vial, and reagent stability post-opening significantly influence final test
costs and, consequently, their cost-effectiveness. Moreover, integrating these tests
into programs targeting TB preventive treatment scale up could stimulate local
innovation and foster competition to meet regional demand. Recurrent consumable
stock-outs could also be overcome by the availability of different tests. An
additional benefit compared to IGRAs is the absence of implementation costs, given
their long-standing use as standard practice in Brazil and the current efforts to
expand skin test competence in healthcare workers (ExpandTPT project, 2024; personal
communication). Finally, skin tests are provided at the point of care, which enables
a wider availability of these tests in rural and other remote areas.</p><p>An universal limitation of economic analyses of TB infection detection and treatment
is related to the sensitivity of tests. Since no golden standard exists for TB
infection diagnosis, these economic analyses are based on studies performed in
populations with TB, in whom TST, TBST, and IGRA tests, which are based on immune
response, may show lower sensitivity <xref rid="B42" ref-type="bibr">
<sup>42</sup>
</xref>. Previous studies were also sensitive to TB infection incidence, a parameter
with a high degree of uncertainty among healthcare workers <xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref>. We used a large range of TB infection incidence (9%-24%) in our sensitivity
analysis, and there was no impact in the final conclusion.</p><p>This study shows several limitations. Firstly, decision analyses inherently depend on
the quality and accuracy of their base-case modeling parameter values. We did not
consider drug-resistant TB strains due to their modest prevalence in Brazil and the
current recommendation not to treat contacts of persons with drug-resistant TB <xref rid="B43" ref-type="bibr">
<sup>43</sup>
</xref>. Moreover, we did not consider the entire TB spectrum (incipient and
sub-clinical disease) <xref rid="B44" ref-type="bibr">
<sup>44</sup>
</xref>, as no commercially available tests or treatment implications exist for
other TB status. Additionally, our model is based on numerous assumptions. We tested
the potential impact of major assumptions using sensitivity analyses, while others
were assumed as fixed. For instance, our study did not model HIV infection, TB
treatment dropout rates, or skin test booster effects. We also did not address the
cost-effectiveness of baseline screening at hiring, which is necessary to identify
workers who would benefit from subsequent tests and to interpret the results,
regardless of the specific test and frequency adopted. We did not consider costs for
repeated skin tests in cases of lost readings, but we estimated the rate of
non-return at 3% <xref rid="B45" ref-type="bibr">
<sup>45</sup>
</xref>. Finally, due to the lack of a threshold reference for case avoidance in
Brazil, we opted to use the QALY threshold as a reference, which has been the metric
used for the incorporation of technologies into the SUS, notwithstanding the
limitations of this comparison <xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B38" ref-type="bibr">
<sup>38</sup>
</xref>.</p><p>Despite these limitations, this cost-effectiveness analysis can contribute to
decision-making in Brazil and serve as a reference for economic evaluations in other
countries. The findings suggest that alternatives to the QFT-Plus approach may be
worth considering, as these new tests could potentially facilitate the scale-up of
TB prevention programs and contribute to global TB control efforts. Importantly,
these alternatives may not require venipuncture or the use of costly laboratory
facilities.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Departamento de Ci&#x000ea;ncia e Tecnologia. Secretaria de Ci&#x000ea;ncia.
Tecnologia e Insumos Estrat&#x000e9;gicos. Minist&#x000e9;rio da Sa&#x000fa;de</collab>
</person-group><source>Diretrizes metodol&#x000f3;gicas: diretriz de avalia&#x000e7;&#x000e3;o econ&#x000f4;mica</source><year>2014</year><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>United Nations</collab>
</person-group><source>Resolution adopted by the General Assembly on 10 October 2019.</source><comment>
<ext-link xlink:href="https://undocs.org/en/A/RES/74/2" ext-link-type="uri">https://undocs.org/en/A/RES/74/2</ext-link>
</comment><date-in-citation content-type="access-date" iso-8601-date="2022-03-30">30/Mar/2022</date-in-citation></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Apriani</surname><given-names>L</given-names></name>
<name><surname>McAllister</surname><given-names>S</given-names></name>
<name><surname>Sharples</surname><given-names>K</given-names></name>
<name><surname>Alisjahbana</surname><given-names>B</given-names></name>
<name><surname>Ruslami</surname><given-names>R</given-names></name>
<name><surname>Hill</surname><given-names>PC</given-names></name>
</person-group><article-title>Latent tuberculosis infection in health care workers in low and
middle-income countries an updated systematic review</article-title><source>Eur Respir J</source><year>2019</year><volume>53</volume><fpage>1801789</fpage><lpage>1801789</lpage><pub-id pub-id-type="pmid">30792341</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Minist&#x000e9;rio da Sa&#x000fa;de</collab>
</person-group><source>Protocolo de vigil&#x000e2;ncia da infec&#x000e7;&#x000e3;o latente pelo Mycobacterium
tuberculosis no Brasil</source><year>2022</year><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Schwartzman</surname><given-names>K</given-names></name>
</person-group><article-title>Referrals for positive tuberculin tests in new health care
workers and students a retrospective cohort study</article-title><source>BMC Public Health</source><year>2010</year><volume>10</volume><fpage>28</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">20089163</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>WHO consolidated guidelines on tuberculosis. Module 1: prevention.
Tuberculosis preventive treatment</source><year>2021</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><article-title>Nationwide shortage of tuberculin skin test antigens: CDC
recommendations for patient care and public health practice.</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2019</year><volume>68</volume><fpage>552</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">31220054</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="legal-doc"><person-group person-group-type="author">
<collab>Minist&#x000e9;rio da Sa&#x000fa;de</collab>
</person-group><article-title>Portaria SCTIE/MS n&#x000ba; 50, de 11 de novembro de 2020. Torna p&#x000fa;blica
a decis&#x000e3;o de incorporar o teste de libera&#x000e7;&#x000e3;o de interferon-gama (interferon
gamma release assay - IGRA) para detec&#x000e7;&#x000e3;o de tuberculose latente em pessoas
vivendo com HIV, crian&#x000e7;as em contato com casos de tuberculose ativa e
pacientes candidatos a transplante de c&#x000e9;lulas-tronco.</article-title><source>Di&#x000e1;rio Oficial da Uni&#x000e3;o</source><day>13</day><month>11</month><year>2020</year></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Coordena&#x000e7;&#x000e3;o-Geral de Vigil&#x000e2;ncia das Doen&#x000e7;as de Transmiss&#x000e3;o
Respirat&#x000f3;ria de Condi&#x000e7;&#x000f5;es Cr&#x000f4;nicas. Departamento de Doen&#x000e7;as de Condi&#x000e7;&#x000f5;es
Cr&#x000f4;nicas e Infec&#x000e7;&#x000f5;es Sexualmente Transmiss&#x000ed;veis. Secretaria de
Vigil&#x000e2;ncia em Sa&#x000fa;de. Minist&#x000e9;rio da Sa&#x000fa;de</collab>
</person-group><source>Nota Informativa n&#x000ba; 1/2022-CGDR/.DCCI/SVS/MS</source><year>2022</year><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diel</surname><given-names>R</given-names></name>
<name><surname>Lampenius</surname><given-names>N</given-names></name>
<name><surname>Nienhaus</surname><given-names>A</given-names></name>
</person-group><article-title>Cost effectiveness of preventive treatment for tuberculosis in
special high-risk populations</article-title><source>Pharmacoeconomics</source><year>2015</year><volume>33</volume><fpage>783</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">25774015</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loureiro</surname><given-names>RB</given-names></name>
<name><surname>Maciel</surname><given-names>ELN</given-names></name>
<name><surname>Caetano</surname><given-names>R</given-names></name>
<name><surname>Peres</surname><given-names>RL</given-names></name>
<name><surname>Fregona</surname><given-names>G</given-names></name>
<name><surname>Golub</surname><given-names>JE</given-names></name>
</person-group><article-title>Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus
tuberculin skin test for diagnosis and treatment of latent tuberculosis
infection in primary health care workers in Brazil</article-title><source>PLoS One</source><year>2019</year><volume>14</volume><elocation-id>e0225197</elocation-id><pub-id pub-id-type="pmid">31725786</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Steffen</surname><given-names>RE</given-names></name>
<name><surname>Pinto</surname><given-names>M</given-names></name>
<name><surname>Kritski</surname><given-names>A</given-names></name>
<name><surname>Trajman</surname><given-names>A</given-names></name>
</person-group><article-title>Cost-effectiveness of newer technologies for the diagnosis of
Mycobacterium tuberculosis infection in Brazilian people living with
HIV</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>21823</fpage><lpage>21823</lpage><pub-id pub-id-type="pmid">33311520</pub-id>
</element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Minist&#x000e9;rio da Sa&#x000fa;de</collab>
</person-group><source>Manual de recomenda&#x000e7;&#x000f5;es para o controle da tuberculose no
Brasil.</source><edition>2nd</edition><year>2018</year><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sepkowitz</surname><given-names>KA</given-names></name>
</person-group><article-title>How contagious is tuberculosis</article-title><source>Clin Infect Dis</source><year>1996</year><volume>23</volume><fpage>954</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">8922785</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones-L&#x000f3;pez</surname><given-names>EC</given-names></name>
<name><surname>Namugga</surname><given-names>O</given-names></name>
<name><surname>Mumbowa</surname><given-names>F</given-names></name>
<name><surname>Ssebidandi</surname><given-names>M</given-names></name>
<name><surname>Mbabazi</surname><given-names>O</given-names></name>
<name><surname>Moine</surname><given-names>S</given-names></name>
</person-group><article-title>Cough aerosols of Mycobacterium tuberculosis predict new
infection a household contact study</article-title><source>Am J Respir Crit Care Med</source><year>2013</year><volume>187</volume><fpage>1007</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">23306539</pub-id>
</element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sutherland</surname><given-names>I</given-names></name>
</person-group><article-title>The evolution of clinical tuberculosis in
adolescents</article-title><source>Tubercle</source><year>1966</year><volume>47</volume><fpage>308</fpage><lpage>308</lpage></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cardona</surname><given-names>PJ</given-names></name>
</person-group><article-title>Reactivation or reinfection in adult tuberculosis is that the
question?</article-title><source>Int J Mycobacteriol</source><year>2016</year><volume>5</volume><fpage>400</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">27931680</pub-id>
</element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nasreen</surname><given-names>S</given-names></name>
<name><surname>Shokoohi</surname><given-names>M</given-names></name>
<name><surname>Malvankar-Mehta</surname><given-names>MS</given-names></name>
</person-group><article-title>Prevalence of latent tuberculosis among health care workers in
high burden countries a systematic review and meta-analysis</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><elocation-id>e0164034</elocation-id><pub-id pub-id-type="pmid">27711155</pub-id>
</element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Habibzadeh</surname><given-names>F</given-names></name>
<name><surname>Yadollahie</surname><given-names>M</given-names></name>
</person-group><article-title>Number needed to misdiagnose a measure of diagnostic test
effectiveness</article-title><source>Epidemiology</source><year>2013</year><volume>24</volume><fpage>170</fpage><lpage>170</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>JR</given-names></name>
<name><surname>Winters</surname><given-names>N</given-names></name>
<name><surname>Menzies</surname><given-names>D</given-names></name>
</person-group><article-title>Absolute risk of tuberculosis among untreated populations with a
positive tuberculin skin test or interferon-gamma release assay result
systematic review and meta-analysis</article-title><source>BMJ</source><year>2020</year><volume>368</volume><fpage>m549</fpage><lpage>m549</lpage><pub-id pub-id-type="pmid">32156698</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alsdurf</surname><given-names>H</given-names></name>
<name><surname>Hill</surname><given-names>PC</given-names></name>
<name><surname>Matteelli</surname><given-names>A</given-names></name>
<name><surname>Getahun</surname><given-names>H</given-names></name>
<name><surname>Menzies</surname><given-names>D</given-names></name>
</person-group><article-title>The cascade of care in diagnosis and treatment of latent
tuberculosis infection a systematic review and meta-analysis</article-title><source>Lancet Infect Dis</source><year>2016</year><volume>16</volume><fpage>1269</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">27522233</pub-id>
</element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ziakas</surname><given-names>PD</given-names></name>
<name><surname>Mylonakis</surname><given-names>E</given-names></name>
</person-group><article-title>4 months of rifampin compared with 9 months of isoniazid for the
management of latent tuberculosis infection a meta-analysis and
cost-effectiveness study that focuses on compliance and liver
toxicity</article-title><source>Clin Infect Dis</source><year>2009</year><volume>49</volume><fpage>1883</fpage><lpage>1889</lpage><pub-id pub-id-type="pmid">19911936</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kahwati</surname><given-names>LC</given-names></name>
<name><surname>Feltner</surname><given-names>C</given-names></name>
<name><surname>Halpern</surname><given-names>M</given-names></name>
<name><surname>Woodell</surname><given-names>CL</given-names></name>
<name><surname>Boland</surname><given-names>E</given-names></name>
<name><surname>Amick</surname><given-names>HR</given-names></name>
</person-group><article-title>Primary care screening and treatment for latent tuberculosis
infection in adults evidence report and systematic review for the US
Preventive Services Task Force</article-title><source>JAMA</source><year>2016</year><volume>316</volume><fpage>970</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">27599332</pub-id>
</element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smieja</surname><given-names>MJ</given-names></name>
<name><surname>Marchetti</surname><given-names>CA</given-names></name>
<name><surname>Cook</surname><given-names>DJ</given-names></name>
<name><surname>Smaill</surname><given-names>FM</given-names></name>
</person-group><article-title>Isoniazid for preventing tuberculosis in non-HIV infected
persons</article-title><source>Cochrane Database Syst Rev</source><year>2000</year><issue>2</issue><fpage>CD001363</fpage><lpage>CD001363</lpage><pub-id pub-id-type="pmid">10796642</pub-id>
</element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krutikov</surname><given-names>M</given-names></name>
<name><surname>Faust</surname><given-names>L</given-names></name>
<name><surname>Nikolayevskyy</surname><given-names>V</given-names></name>
<name><surname>Hamada</surname><given-names>Y</given-names></name>
<name><surname>Gupta</surname><given-names>RK</given-names></name>
<name><surname>Cirillo</surname><given-names>D</given-names></name>
</person-group><article-title>The diagnostic performance of novel skin-based in-vivo tests for
tuberculosis infection compared with purified protein derivative tuberculin
skin tests and blood-based in vitro interferon- release assays: a systematic
review and meta-analysis</article-title><source>Lancet Infect Dis</source><year>2021</year><volume>22</volume><fpage>250</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">34606768</pub-id>
</element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Starshinova</surname><given-names>A</given-names></name>
<name><surname>Dovgalyk</surname><given-names>I</given-names></name>
<name><surname>Malkova</surname><given-names>A</given-names></name>
<name><surname>Zinchenko</surname><given-names>Y</given-names></name>
<name><surname>Pavlova</surname><given-names>M</given-names></name>
<name><surname>Belyaeva</surname><given-names>E</given-names></name>
</person-group><article-title>Recombinant tuberculosis allergen (Diaskintest) in tuberculosis
diagnostic in Russia (meta-analysis)</article-title><source>Int J Mycobacteriol</source><year>2020</year><volume>9</volume><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">33323648</pub-id>
</element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>Use of alternative interferon-gamma release assays for the diagnosis of
TB infection: WHO policy statement</source><year>2022</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>SK</given-names></name>
<name><surname>Sharma</surname><given-names>A</given-names></name>
<name><surname>Kadhiravan</surname><given-names>T</given-names></name>
<name><surname>Tharyan</surname><given-names>P</given-names></name>
</person-group><article-title>Rifamycins (rifampicin, rifabutin and rifapentine) compared to
isoniazid for preventing tuberculosis in HIV-negative people at risk of
active TB</article-title><source>Evid Based Child Health</source><year>2014</year><volume>9</volume><fpage>169</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">25404581</pub-id>
</element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melnychuk</surname><given-names>L</given-names></name>
<name><surname>Perlman-Arrow</surname><given-names>S</given-names></name>
<name><surname>Bastos</surname><given-names>ML</given-names></name>
<name><surname>Menzies</surname><given-names>D</given-names></name>
</person-group><article-title>A systematic review and meta-analysis of tuberculous preventative
therapy adverse events</article-title><source>Clin Infect Dis</source><year>2023</year><volume>77</volume><fpage>287</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">37125482</pub-id>
</element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oh</surname><given-names>CE</given-names></name>
<name><surname>Ortiz-Brizuela</surname><given-names>E</given-names></name>
<name><surname>Bastos</surname><given-names>ML</given-names></name>
<name><surname>Menzies</surname><given-names>D</given-names></name>
</person-group><article-title>Comparing the diagnostic performance of qft-plus to other tests
of latent tuberculosis infection a systematic review and
meta-analysis</article-title><source>Clin Infect Dis</source><year>2020</year><volume>73</volume><fpage>e1116</fpage><lpage>e1125</lpage></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gidwani</surname><given-names>R</given-names></name>
<name><surname>Russell</surname><given-names>LB</given-names></name>
</person-group><article-title>Estimating transition probabilities from published evidence a
tutorial for decision modelers</article-title><source>Pharmacoeconomics</source><year>2020</year><volume>38</volume><fpage>1153</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">32797380</pub-id>
</element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Instituto Brasileiro de Geografia e Estat&#x000ed;stica</collab>
</person-group><source>T&#x000e1;buas completas de mortalidade.</source><comment>
<ext-link xlink:href="https://www.ibge.gov.br/estatisticas/sociais/populacao/9126-tabuas-completas-de-mortalidade.html?=&#x00026;t=resultados" ext-link-type="uri">https://www.ibge.gov.br/estatisticas/sociais/populacao/9126-tabuas-completas-de-mortalidade.html?=&#x00026;t=resultados</ext-link>
</comment><date-in-citation content-type="access-date" iso-8601-date="2021-10-05">05/Oct/2021</date-in-citation></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Minist&#x000e9;rio da Sa&#x000fa;de</collab>
</person-group><source>Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM
do SUS.</source><comment>
<ext-link xlink:href="http://sigtap.datasus.gov.br/tabela-unificada/app/sec/procedimento/publicados/consultar" ext-link-type="uri">http://sigtap.datasus.gov.br/tabela-unificada/app/sec/procedimento/publicados/consultar</ext-link>
</comment><date-in-citation content-type="access-date" iso-8601-date="2022-07-01">01/Jul/2022</date-in-citation></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Steffen</surname><given-names>R</given-names></name>
<name><surname>Menzies</surname><given-names>D</given-names></name>
<name><surname>Oxlade</surname><given-names>O</given-names></name>
<name><surname>Pinto</surname><given-names>M</given-names></name>
<name><surname>de Castro</surname><given-names>AZ</given-names></name>
<name><surname>Monteiro</surname><given-names>P</given-names></name>
</person-group><article-title>Patients' costs and cost-effectiveness of tuberculosis treatment
in dots and non-dots facilities in Rio de Janeiro, Brazil</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><elocation-id>e14014</elocation-id><pub-id pub-id-type="pmid">21103344</pub-id>
</element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Banco Central do Brasil</collab>
</person-group><source>Cota&#x000e7;&#x000f5;es e boletins.</source><comment>
<ext-link xlink:href="https://www.bcb.gov.br/estabilidadefinanceira/historicocotacoes" ext-link-type="uri">https://www.bcb.gov.br/estabilidadefinanceira/historicocotacoes</ext-link>
</comment><date-in-citation content-type="access-date" iso-8601-date="2023-01-10">10/Jan/2023</date-in-citation></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turner</surname><given-names>HC</given-names></name>
<name><surname>Lauer</surname><given-names>JA</given-names></name>
<name><surname>Tran</surname><given-names>BX</given-names></name>
<name><surname>Teerawattananon</surname><given-names>Y</given-names></name>
<name><surname>Jit</surname><given-names>M</given-names></name>
</person-group><article-title>Adjusting for inflation and currency changes within health
economic studies</article-title><source>Value Health</source><year>2019</year><volume>22</volume><fpage>1026</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">31511179</pub-id>
</element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Partnership</surname><given-names>ST</given-names></name>
</person-group><source>Global drug facility medicines catalog. February 2022.</source><comment>
<ext-link xlink:href="https://www.stoptb.org/sites/default/files/gdfmedicinescatalog_1.pdf" ext-link-type="uri">https://www.stoptb.org/sites/default/files/gdfmedicinescatalog_1.pdf</ext-link>
</comment><date-in-citation content-type="access-date" iso-8601-date="2022-02-01">01/Feb/2022</date-in-citation></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Minist&#x000e9;rio da Sa&#x000fa;de</collab>
</person-group><source>O uso de limiares de custo-efetividade</source><year>2022</year><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Husereau</surname><given-names>D</given-names></name>
<name><surname>Drummond</surname><given-names>M</given-names></name>
<name><surname>Augustovski</surname><given-names>F</given-names></name>
<name><surname>de Bekker-Grob</surname><given-names>E</given-names></name>
<name><surname>Briggs</surname><given-names>AH</given-names></name>
<name><surname>Carswell</surname><given-names>C</given-names></name>
</person-group><article-title>Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) 2022 Explanation and elaboration: a report of the ISPOR CHEERS II
Good Practices Task Force</article-title><source>Value Health</source><year>2022</year><volume>25</volume><fpage>10</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">35031088</pub-id>
</element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alsdurf</surname><given-names>H</given-names></name>
<name><surname>Oxlade</surname><given-names>O</given-names></name>
<name><surname>Adjobimey</surname><given-names>M</given-names></name>
<name><surname>Ahmad Khan</surname><given-names>F</given-names></name>
<name><surname>Bastos</surname><given-names>M</given-names></name>
<name><surname>Bedingfield</surname><given-names>N</given-names></name>
</person-group><article-title>Resource implications of the latent tuberculosis cascade of care
a time and motion study in five countries</article-title><source>BMC Health Serv Res</source><year>2020</year><volume>20</volume><fpage>341</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">32316963</pub-id>
</element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>WHO operational handbook on tuberculosis. Module 3: diagnosis. Tests for
tuberculosis infection</source><year>2022</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pai</surname><given-names>M</given-names></name>
<name><surname>Zwerling</surname><given-names>A</given-names></name>
<name><surname>Menzies</surname><given-names>D</given-names></name>
</person-group><article-title>Systematic review T-cell-based assays for the diagnosis of latent
tuberculosis infection: an update</article-title><source>Ann Intern Med</source><year>2008</year><volume>149</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">18593687</pub-id>
</element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bastos</surname><given-names>ML</given-names></name>
<name><surname>Cosme</surname><given-names>LB</given-names></name>
<name><surname>Fregona</surname><given-names>G</given-names></name>
<name><surname>do Prado</surname><given-names>TN</given-names></name>
<name><surname>Bertolde</surname><given-names>AI</given-names></name>
<name><surname>Zandonade</surname><given-names>E</given-names></name>
</person-group><article-title>Treatment outcomes of MDR-tuberculosis patients in Brazil a
retrospective cohort analysis</article-title><source>BMC Infect Dis</source><year>2017</year><volume>17</volume><fpage>718</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">29137626</pub-id>
</element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drain</surname><given-names>PK</given-names></name>
<name><surname>Bajema</surname><given-names>KL</given-names></name>
<name><surname>Dowdy</surname><given-names>D</given-names></name>
<name><surname>Dheda</surname><given-names>K</given-names></name>
<name><surname>Naidoo</surname><given-names>K</given-names></name>
<name><surname>Schumacher</surname><given-names>SG</given-names></name>
</person-group><article-title>Incipient and subclinical tuberculosis a clinical review of early
stages and progression of infection</article-title><source>Clin Microbiol Rev</source><year>2018</year><volume>31</volume><fpage>e00021</fpage><lpage>e00018</lpage></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souza</surname><given-names>FM</given-names></name>
<name><surname>Prado</surname><given-names>TN</given-names></name>
<name><surname>Pinheiro</surname><given-names>JS</given-names></name>
<name><surname>Peres</surname><given-names>RL</given-names></name>
<name><surname>Lacerda</surname><given-names>TC</given-names></name>
<name><surname>Loureiro</surname><given-names>RB</given-names></name>
</person-group><article-title>Comparison of interferon-c release assay to two cut-off points of
tuberculin skin test to detect latent Mycobacterium tuberculosis infection
in primary health care workers</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><elocation-id>e102773</elocation-id><pub-id pub-id-type="pmid">25137040</pub-id>
</element-citation></ref></ref-list></back></article>